Washington, DC-based FDA & Biotechnology practice group shareholder Barbara Binzak Blumenfeld presented on drug supply chain issues to the BIOCOM Regulatory Affairs Committee in San Diego on April 20. Her presentation, “The Drug Supply Chain Security Act – Four Years Later” identified the provisions of the law that are currently in effect and what they mean for the drug industry, and addressed the requirements that will go into effect by the end of the 10-year implementation period in 2023.
BIOCOM was founded in 1995 as a leader and advocate for the life science sector in California. Headquartered in San Diego, BIOCOM currently represents over 850 members. BIR joined BIOCOM in 2017, and Barbara is a member of the Regulatory Affairs Committee.